Findings

What do systematic reviews say?

178 questions · 179 findings · 80 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 104 · 58.1%GRADE not reported 6 · 3.4%Very low 18 · 10.1%Low 31 · 17.3%Moderate 16 · 8.9%High 4 · 2.2%

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

Quality of life · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: tobramycin for inhalation powder vs tobramycin

Quality of life · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Adjuvant chemotherapy vs no chemotherapy

Health‐related quality of life · people with resectable cholangiocarcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Radioembolisation vs chemoembolisation

Health‐related quality of life · people with hepatocellular carcinoma

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Very low

Radioembolisation plus sorafenib vs sorafenib monotherapy

Health‐related quality of life · people with hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Radioembolisation vs sorafenib monotherapy

Health‐related quality of life · people with hepatocellular carcinoma

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 360 participants
Very low

Azelaic acid vs tretinoin

Quality of life · participants with acne

The review found no eligible studies for this question.

1 finding from 1 review

Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha‐hydroxy acid) for acne 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

N‐acetylcysteine vs placebo

Quality of life ‐ not reported · children with non‐paracetamol (acetaminophen)‐related acute liver failure

The review found no eligible studies for this question.

1 finding from 1 review

N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tivozanib vs sorafenib (targeted agent versus targeted agent)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 506 participants
Low

Sunitinib vs everolimus (targeted agent versus targeted agent)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 288 participants
Low

Sunitinib vs atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 691 participants
Low

Sunitinib vs IFN‐α (targeted agent versus classic immunotherapy)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 544 participants
Moderate

Temsirolimus vs IFN‐α (targeted agent versus classic immunotherapy)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 401 participants
Low

Sunitinib vs atezolizumab (targeted therapy versus immunotherapy)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 157 participants
Low

Temsirolimus + IFN‐α vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 394 participants
Low

Sunitinib vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 460 participants
Moderate

Pazopanib vs placebo (targeted agent versus placebo)

Health‐related quality of life · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 300 participants
High

TACE followed by 3‐DCRT vs chemoembolisation

Health‐related quality of life · primary hepatocellular carcinoma

1 finding from 1 review

Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 66 participants
Very low

PGE1 vs inositol niacinate

Quality of life · people with critical limb ischaemia

The review found no eligible studies for this question.

1 finding from 1 review

Prostanoids for critical limb ischaemia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus cisplatin vs S‐1 plus cisplatin

Health‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found